Arrien pharmaceutical's drug discovery objectives and success are reflected from the experiences in Medicinal Chemistry and Pharmaceutical Industry, which enabled to execute its product pipeline in a short period of time. Arrien cost-competent approach evolved from its FFDD™ technology and influenced the target-specific leads for multiple protein targets. Moreover, the company technology has proven in the identification of potent and highly selective protein kinase inhibitors. The technology immensely involves large-scale in-silico screening with the application proprietary FFDD™ workflows, ideal candidate property predictions, early phase safety pharmacology and target specific screening for novel chemical entities are critical to current drug discovery processes.